Jefferies Group’s Cartesian Therapeutics RNAC Stock Holding History

Jefferies Group’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-514	Closed	-$41K	–	2578
2018 Q4	$41K	Buy	+514	New	+$117K	﹤0.01%	2044

Other funds holding RNAC

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's RNAC Position: Q1 2019 in Review

Jefferies Group sold out of Cartesian Therapeutics (RNAC) in Q1 2019, closing a stake of 514 shares — an estimated $41K sold.

Jefferies Group first reported a position in RNAC in Q4 2018 and held it in 1 quarter. The position peaked at $41K in Q4 2018. 56 funds tracked by Wall St. Rank hold RNAC as of Q1 2019.

Jefferies Group reported no remaining Cartesian Therapeutics position as of Q1 2019 after selling out during the quarter.
Jefferies Group sold 514 Cartesian Therapeutics shares in Q1 2019, an estimated $41K.
Jefferies Group first reported a position in Cartesian Therapeutics in Q4 2018 and held it in 1 quarter.
Jefferies Group's Cartesian Therapeutics position peaked at $41K in Q4 2018.
56 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.